| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CX-5461 | GDSC1000 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | STF-62247 | GDSC1000 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | QL-XII-47 | GDSC1000 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | -0.025 | 0.6 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | BRD-K49290616 | CTRPv2 | pan-cancer | AAC | -0.043 | 0.6 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |